Pharmaxis Announces First Relaunch Sales of Aridol in USA
Filed with ASX · · 2 pages · English
Story so far
Earlier from Syntara
- Pharmaxis AGM - CEO Presentation
- LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
- Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
- Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
- FDA Factory Approval and Relaunch of Aridol in US Market
Later from Syntara
- Pharmaxis announces resubmission of bronchitol nda in usa
- Pharmaxis Announces LOXL2 Program Phase 2 Ready
- Quarterly Shareholder Update - December 2018
- Pharmaxis Commences Phase 1 LOX Clinical Trial
- Quarterly Shareholder Update - March 2019
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara